CT-388
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Roche · Phase 3 · Recruiting · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Enicepatide Dose 1 | n/r | n/r | n/r | n/r |
| Enicepatide Dose 2 | n/r | n/r | n/r | n/r |
| Enicepatide Dose 3 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Enicepatide Dose 1: endpoint not reported
- Enicepatide Dose 2: endpoint not reported
- Enicepatide Dose 3: endpoint not reported
- Placebo: endpoint not reported